INNOVATIVEPHAR：EnvironmentalSocialAndGovernanceReport2024-25.pdf

1、ENVIRONMENTAL,SOCIAL ANDGOVERNANCE REPORT2024/25環境、社會及管治報告(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)(於開曼群島註冊成立並於百慕達存續之有限公司)(Stock Code 股份代號：399)(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)(於開曼群島註冊成立並於百慕達存續之有限公司)(Stock

2、Code 股份代號：399)Annual Report 2025年報IntroductionABOUT THE GROUPInnovative Pharmaceutical Biotech Limited(the“Company”,together with its subsidiaries,the“Group”or“we”)is a medical and biotechnology Hong Kong investment holding company operating in two major segments,including(a)trading of beauty produc

3、ts in Hong Kong(“trading of beauty products”);(b)research,development and commercialisation of the oral insulin product(“research and development”).This Environmental,Social and Governance Report(the“Report”)summarises the environmental,social and governance(“ESG”)initiatives,plans and performances

4、of the Group and demonstrates its commitment to sustainability development.The Group adheres to the management policies of sustainable development on the ESG aspects.We are also committed to handling our ESG affairs effectively and responsibly,which is integrated as one of the core components of our

5、 business strategy as we believe this is the key to our continuous success in the future.ESG GOVERNANCE STRUCTUREThe Group has established an ESG governance structure to ensure that its ESG governance is consistent with its business strategies and to integrate ESG management into its operational and

6、 decision-making processes.The Board of Directors(the“Board”)assesses the potential impact of ESG issues on the overall strategy of the Group,sets out main direction for the ESG management approach and strategy,supervises the management of the Groups ESG issues,and ensures the effectiveness of the r